Well the guidance if you include Jac for FY (and add back the $1m est costs) gets you to $90m U EBITDA. Jac f/c FY17 was 32m, Cont EBITDA was 51m, and there is $7m of growth on a base of 83, which is 8.4% growth on that base. Also Jac earned 9m ebitda - that is 28% of the FY for last year, in two months, rather than 3.5 months. Guidance may also be conservative.
All sounds good to me on that basis - keen to know if I am missing something - so please let me know.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.35 |
Change
-0.140(3.12%) |
Mkt cap ! $1.571B | |||
| Open | High | Low | Value | Volume |
| $4.49 | $4.52 | $4.27 | $30.42M | 7.018M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $4.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.37 | 500 | 1 |
View Market Depth
| Last trade - 16.17pm 27/06/2025 (20 minute delay) ? |
| WEB (ASX) Chart |